CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma
Authors
R. Hájek Minarík, J. Straub, J. Pour, L. Jungova, A. Berdeja, J.G. Boccadoro, M. Brozova, L. Spencer, A. Van Rhee, F. Vela-Ojeda, J. Thompson, M.A. Abonour, R. Chari, A. Cook, G. Costello, C.L. Davies, F.E. Hungria, V.T.M. Lee, H.C. Leleu, X. Puig, N. Rifkin, R.M. Terpos, E. Usmani, S.Z. Weisel, K.C. Zonder, J.A. Barinová, M. Kuhn, M. Šilar, J. Cápková, L. Galvez, K. Lu, J. Elliott, J. Stull, D.M. Ren, K. Maisnar, V.
Publication date
1 January 2021
Publisher
Abstract
Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov)</ext-link. © 2021 Future Medicine Ltd.. All rights reserved
Similar works
Full text
Available Versions
Pergamos : Unified Institutional Repository / Digital Library Platform of the National and Kapodistrian University of Athens
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:lib.uoa.gr:uoadl:3077072
Last time updated on 10/02/2023